Concepedia

Author

Paulina Selaru

Pfizer (United States)

Also Known As

Brahmer, Julie R., P Selaru, P. Selaru, Paulina Selaru

33

Publications

3.9K

Citations

18

H-Index

24

Concepts

All Affiliations

Pfizer (United States)Chinese Academy of Medical Sciences & Peking Union Medical CollegeMemorial Sloan Kettering Cancer CenterSeoul National University HospitalPfizer (Italy)
PS

About

Paulina Selaru is an author at Pfizer (United States) specializing in medicine, pharmacology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

1.2K

2

Health Sciences

1

1

59

3

Applied Physiology

1

1

59

4

Exercise Physiology

1

1

59

5

Immunology

1

1

108

Paulina Selaru

×

21

Publications

3.9K

Citations

18

H-Index

YearCitations

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Alice T. Shaw, Beow Y. Yeap, Benjamin Solomon,

The Lancet Oncology

2011

880

Clinical Experience With Crizotinib in Patients With Advanced <i>ALK</i>-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

Daniel B. Costa, Alice T. Shaw, Sai‐Hong Ignatius Ou,

Journal of Clinical Oncology

2015

603

Acute Hemodynamic Effects of Conivaptan, a Dual V <sub>1A</sub> and V <sub>2</sub> Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure

James E. Udelson, William Smith, G Hendrix,

Circulation

2001

361

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

Mark A. Socinski, Silvia Novello, Julie R. Brahmer,

Journal of Clinical Oncology

2008

320

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced <i>ALK</i>-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014

Benjamin Solomon, Federico Cappuzzo, Enriqueta Felip,

Journal of Clinical Oncology

2016

270

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Eric B. Haura, Alejandro D. Ricart, Timothy Larson,

Clinical Cancer Research

2010

234

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

S.-H.I. Ou, Pasi A. Jänne, Cynthia Huang Bartlett,

Annals of Oncology

2014

220

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

Giorgio V. Scagliotti, Maciej Krzakowski, Aleksandra Szczęsna,

Journal of Clinical Oncology

2012

211

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

Yi‐Long Wu, Shun Lü, You Lü,

Journal of Thoracic Oncology

2018

181

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

Silvia Novello, Giorgio V. Scagliotti, Rafael Rosell,

British Journal of Cancer

2009

132

Page 1